efficacyAgainstSymptomaticCOVID19
19
triples
GPTKB property
Random triples
| Subject | Object |
|---|---|
| gptkb:CanSino_COVID-19_vaccine | ~65% |
| gptkb:ChAdOx1_nCoV-19 | 60–80% |
| gptkb:COVID-19_Vaccine_(Vaxzevria) | ~70% |
| gptkb:AstraZeneca_COVID-19_vaccine | ~70% |
| gptkb:Ad5-nCoV | ~65% |
| gptkb:ChAdOx1-S | about 70% |
| gptkb:BBIBP-CorV | ~79% |
| gptkb:COVID-19_vaccine_(BBIBP-CorV) | ~79% |
| gptkb:Oxford-AstraZeneca | ~70% |
| gptkb:Covaxin_COVID-19_vaccine | 77.8% |
| gptkb:Nuvaxovid | ~90% |
| gptkb:NVX-CoV2373 | ~90% |
| gptkb:CoronaVac_vaccine | 51% (Brazil trial) |
| gptkb:Soberana_02_vaccine | approximately 62% after two doses |
| gptkb:Novavax_COVID-19_vaccine | ~90% (original strain, clinical trials) |
| gptkb:Abdala_vaccine | 92.28% |
| gptkb:Covishield | about 70% |
| gptkb:CoronaVac | 51% (Brazil trial) |
| gptkb:BBIBP-CorV_COVID-19_vaccine | 79% |